Use of midodrine (Gutron) to treat permanent hypotension in a chronic hemodialysis patient.
Chronic hypotension, infrequent though possible in chronic renal failure patients on hemodialysis, has harmful consequences on their physical state and hence general well-being. These patients often experience acute intradialytic manifestations while non-pharmacologic interventions as pharmacologic agents are sometimes insufficient to improve symptoms. Well tolerated, midodrine appears to be a suitable and effective agent as it raises blood pressure significantly via its effect on peripheral alpha-adrenergic receptors. The authors describe their use of midodrine in a dialysis patient for the longest period of time reported up to now, documented by a pharmacokinetic study, confirming long-term both clinical efficacy and safety of the drug.
Montagnac
R
R
Department of Nephrology-Hemodialysis, Troyes General  Hospital, France.
Clavel
P
P
Delhotal-Landes
B
B
Flouvat
B
B
Poulain
S
S
Schllinger
F
F
D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008879:Midodrine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects*; D014662:Vasoconstrictor Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D008879:Midodrine